ACP-103, a 5-HT2A receptor inverse agonist

Curr Opin Investig Drugs. 2006 Jul;7(7):653-60.

Abstract

ACADIA Pharmaceuticals is developing ACP-103, lead compound in a series of 5-HT2A inverse agonists, as a potential antipsychotic agent and for the potential treatment of insomnia. Phase II clinical trials in treatment-induced psychosis in Parkinson's disease (PD) patients and in schizophrenic patients are ongoing, as are phase II trials evaluating the effects of the drug on PD symptoms and dyskinesias.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Contraindications
  • Humans
  • Piperidines / pharmacology
  • Piperidines / therapeutic use*
  • Piperidines / toxicity
  • Receptor, Serotonin, 5-HT2A / drug effects*
  • Serotonin Receptor Agonists / pharmacology
  • Serotonin Receptor Agonists / therapeutic use*
  • Serotonin Receptor Agonists / toxicity
  • Structure-Activity Relationship
  • Urea / analogs & derivatives*
  • Urea / pharmacology
  • Urea / therapeutic use
  • Urea / toxicity

Substances

  • Piperidines
  • Receptor, Serotonin, 5-HT2A
  • Serotonin Receptor Agonists
  • Urea
  • pimavanserin